The Antiulcerant Drugs Market is expected to register a CAGR of 5% from 2025 to 2031, with a market size expanding from US$ XX million in 2024 to US$ XX Million by 2031.
The report is segmented by Type (Proton pump inhibitors, H2 receptor antagonists, Antibiotics, Gastric mucosal protective drugs, Antacids, Prostaglandin agonists), and Disease (Stomach Ulcers, Leg Ulcers, Peptic Ulcers, Esophageal Ulcer, Bleeding Ulcer, Refractory Ulcer, Stress Ulcer, Mouth Ulcers, Venous Stasis Ulcers, Neuropathic Ulcers, Arterial Ulcers, Pressure Ulcers). The global analysis is broken down at the regional level and for major countries. The market evaluation is presented in US$ for the above segmental analysis.
Purpose of the ReportThe report Antiulcerant Drugs Market by The Insight Partners aims to describe the present landscape and future growth, top driving factors, challenges, and opportunities. This will provide insights to various business stakeholders, such as:
- Technology Providers/Manufacturers: To understand the evolving market dynamics and know the potential growth opportunities, enabling them to make informed strategic decisions.
- Investors: To conduct a comprehensive trend analysis regarding the market growth rate, market financial projections, and opportunities that exist across the value chain.
- Regulatory bodies: To regulate policies and police activities in the market with the aim of minimizing abuse, preserving investor trust and confidence, and upholding the integrity and stability of the market.
Antiulcerant Drugs Market Segmentation
Type- Proton pump inhibitors
- H2 receptor antagonists
- Antibiotics
- Gastric mucosal protective drugs
- Antacids
- Prostaglandin agonists
- Stomach Ulcers
- Leg Ulcers
- Peptic Ulcers
- Esophageal Ulcer
- Bleeding Ulcer
- Refractory Ulcer
- Stress Ulcer
- Mouth Ulcers
- Venous Stasis Ulcers
- Neuropathic Ulcers
- Arterial Ulcers
- Pressure Ulcers
Strategic Insights
Antiulcerant Drugs Market Growth Drivers- Increasing Prevalence of Gastric Disorders: The growing number of people with gastric issues including peptic ulcers acid reflux and GERD drives market expansion for antiulcerant drugs. Medical experts expect antiulcerant drug use to expand because more people develop gastric conditions as the world ages and unhealthy habits persist. The number of people developing peptic ulcers globally keeps rising which pushes doctors to find better ways to treat these patients. More patients take medication for their stomach problems because people understand gastric disorders better and healthcare teams find these conditions sooner. The market for antiulcerant drugs will grow rapidly because there will be more people who need treatment for their conditions. Healthcare providers worldwide can now provide more patients with medicine and use antiulcerant drugs to prevent and treat stomach conditions. The market grows because patients need more PPIs H2 receptor antagonists and antacids. Market growth will increase for pharmaceutical companies that develop gastric ulcer treatment and prevention drugs based on research results.
- Advancements in Drug Formulations and Delivery Systems: The antiulcerant drugs market grows because of new ways to make and deliver medicine. Market projections show that special antiulcerant drugs like long-lasting tablets and targeted delivery systems will succeed in medical treatment during the next years. These updated formulas make medications work better and create fewer side effects while helping patients follow their treatment plans. Pharmaceutical companies now research better ways to deliver treatments that provide prolonged pain relief while being easy to use for patients. Doctors and patients will choose extended-release proton pump inhibitors more often because they protect against stomach acid all day long. Specialized drug delivery systems that aim at specific points in the gastrointestinal tract help reduce unwanted effects from medications. New advanced antiulcerant drugs increase market value when they are launched to patients. Doctors now use advanced drug formulations because these medical treatments are more effective so companies that create these drugs gain market share. Better drug delivery methods and effective treatment options will keep driving the growth of antiulcerant drugs as they help patients with gastric disorders get better results.
- Rising Demand for Over-the-Counter (OTC) Antiulcerant Drugs: More people choose to buy antiulcerant medications without a prescription which makes this market grow stronger. The self-medication habit of people in developed countries is increasing demand for OTC antiulcerant drugs according to market predictions. Because patients want quick relief from acid reflux and digestive problems they use more OTC antiulcerants such as antacids and H2 blockers. People can now manage their mild to moderate symptoms using these drugs without needing a doctor's prescription to buy them. More people with occasional gastric issues now pick OTC antiulcerants because they are easy to get. Manufacturers work hard to make new OTC drugs that work better and look more attractive to buyers. As patients choose to treat their gastric problems more often OTC antiulcerants will take a bigger piece of the total antiulcerant drugs market. People will use more OTC treatments because of their new availability in established and emerging markets which will boost sales of antiulcerant drugs.
- Growth of Biologic Antiulcerant Drugs: Biologic antiulcerant drugs are poised to become a key future trend in the antiulcerant drugs market. The future of ulcer and GERD treatment will depend heavily on market predictions that show how specific inflammatory pathways targeting biologics will help patients. These new medical treatments work to treat the root causes of stomach problems instead of managing symptoms so patients can find permanent relief. Biologic drugs that target proteins that fuel inflammation will become the preferred treatment option for serious ulcers and GERD patients. People now want biological treatments because they believe they will offer better and longer lasting relief than regular drugs. The antiulcerant drugs market will expand because biologics gain wider use. Companies that develop biologics first will gain more market control through these new treatments. The market for antiulcerant drugs will grow strongly because new biologic treatments show better safety and efficacy results.
- Integration of Digital Health and Telemedicine for Treatment Monitoring: Digital health technologies and telemedicine integration in gastric disorder treatment will become more common in the antiulcerant drugs market in the future. Market data shows mobile health apps and telehealth technology will do more to treat acid reflux, GERD, and ulcers in the future. Digital health platforms help patients monitor their medical data including symptom changes and treatment progress without office visits. Using telemedicine patients can get better care from their doctors while digital tools help doctors make treatment changes instantly. The market value of digital health solutions in antiulcerant drug therapy will grow because patients and medical professionals see its benefits for remote monitoring. These technologies let healthcare teams spot issues early and update medications faster to produce better treatment results. Drug manufacturers who combine their products with digital health solutions will capture more market share because digital health integration is growing. The antiulcerant drugs market will expand steadily because digital health and telemedicine keep growing in healthcare.
- Rise in Natural and Herbal Antiulcerant Drugs: People are increasingly seeking natural and herbal antiulcerant drugs as a future market trend. Patients are now exploring plant-based and natural treatments because they want complete gastric disorder management. Market research shows that people want natural remedies that seem to have fewer unwanted effects which drives up demand for herbal antiulcerant drugs. More people use natural ingredients like licorice, ginger, and chamomile because these plants help protect stomach health and fight inflammation. People recognize natural remedies like chamomile and ginger help with stomach problems so they use them more to treat conditions like ulcers and acid reflux. The market for natural and herbal antiulcerants will grow because more people now choose these products over traditional treatments. A company that develops and markets natural antiulcerants will gain more customers in this market segment. The antiulcerant drugs market will grow because more people want plant-based treatments and natural remedies.
- Focus on Combination Therapies: The antiulcerant drugs market will expand through combination therapies for gastric conditions. The market predicts that joining PPI drugs with other treatments especially antibiotics for H. pylori infections will remain popular in the future. The combined use of drugs treats gastric ulcers and acid reflux alongside GERD because different treatment methods are required for each condition. The growth of our market will depend on new combination drugs because healthcare providers and patients will choose these treatments as their preferred option. Manufacturers who create combination therapies have better chances to dominate markets especially in places where medical advances are available to patients. These medical treatments help both symptoms and underlying causes of gastric problems which makes patients more content and achieve better results. Combination therapies will gain market share in emerging areas since these regions have rising numbers of complex gastric disease cases.
- Growth in Biologic Treatments for Severe Gastric Disorders: The antiulcerant drugs market will experience promising growth from new biological treatments that treat severe gastric disorders. Monoclonal antibody biologics prove effective in treating chronic gastric conditions that do not respond to regular treatments. The market projects that biologic treatments for GERD and ulcer patients will generate more demand as new biological antiulcerants receive regulatory approval. Biologic treatments precisely target gastric problems and work better than traditional treatments when standard therapies fail. New biologic treatments entering the antiulcerant drugs market will increase its size because these therapies can help patients dealing with difficult gastric problems. Companies that create effective biologic therapies first will take a larger market share because patients need these advanced treatments. As more scientists develop biologic treatments for stomach ulcers the antiulcerant drugs market will keep expanding.
- Investment in OTC and Generic Drugs: The market holds strong potential for growth because consumers increasingly use over-the-counter and generic antiulcerant drugs. Market data shows people choose self-medication and cheaper generic drugs are fueling this market sector's expansion. People use OTC antiulcerants like antacids H2 blockers and PPIs more because these products help them treat minor heartburn and indigestion episodes with easy access to medicine. As pharmaceutical patents expire manufacturers can now introduce lower-cost generic versions of antiulcerant drugs. Developing nations will see greater use of OTC and generic medications because people there cannot easily get brand-name treatments. Companies that make and sell better quality generic antiulcerants will find more success because patients want affordable treatment options. More patients will get access to antiulcerant drugs through over-the-counter sales and generic options which will expand the market for manufacturers.
Market Report Scope
Key Selling Points
- Comprehensive Coverage: The report comprehensively covers the analysis of products, services, types, and end users of the Antiulcerant Drugs Market, providing a holistic landscape.
- Expert Analysis: The report is compiled based on the in-depth understanding of industry experts and analysts.
- Up-to-date Information: The report assures business relevance due to its coverage of recent information and data trends.
- Customization Options: This report can be customized to cater to specific client requirements and suit the business strategies aptly.
The research report on the Antiulcerant Drugs Market can, therefore, help spearhead the trail of decoding and understanding the industry scenario and growth prospects. Although there can be a few valid concerns, the overall benefits of this report tend to outweigh the disadvantages.
REGIONAL FRAMEWORK
Have a question?

Mrinal
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities
- Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.
- Request discounts available for Start-Ups & Universities

Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
This text is related
to segments covered.

Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
This text is related
to country scope.
Frequently Asked Questions
The Antiulcerant Drugs Market is estimated to witness a CAGR of 5% from 2025 to 2031.
The major factors driving the antiulcerant drugs market are the increasing prevalence of gastric disorders, advancements in drug formulations and delivery systems, and rising demand for over-the-counter (OTC) antiulcerant drugs.
Future trends in the Antiulcerant Drugs Market are Growth of Biologic Antiulcerant Drugs, Integration of Digital Health and Telemedicine for Treatment Monitoring, Rise in Natural and Herbal Antiulcerant Drugs.
Some of the players operating in the market are Dr. Reddy's Laboratories, Ltd, Cipla, Glenmark, Aristo Pharma, Takeda Pharmaceutical Company Limited, Salix Pharmaceuticals, Zydus Cadila, Pfizer, Inc, Fourrts Himalaya Wellness Company.
The report can be delivered in PDF/PPT format; we can also share an excel datasheet based on the request.
Some customization options available based on the request are an additional 3–5 company profiles and a country-specific analysis of 3–5 countries of your choice. Customizations are to be requested/discussed before making final order confirmation# as our team would review the same and check the feasibility.
1. INTRODUCTION
1.1. SCOPE OF THE STUDY
1.2. THE INSIGHT PARTNERS RESEARCH REPORT GUIDANCE
1.3. MARKET SEGMENTATION
1.3.1 Antiulcerant Drugs Market - By Type
1.3.2 Antiulcerant Drugs Market - By Disease
1.3.3 Antiulcerant Drugs Market - By Region
1.3.3.1 By Country
2. KEY TAKEAWAYS
3. RESEARCH METHODOLOGY
4. ANTIULCERANT DRUGS MARKET LANDSCAPE
4.1. OVERVIEW
4.2. PORTER'S FIVE FORCES ANALYSIS
4.2.1 Bargaining Power of Buyers
4.2.1 Bargaining Power of Suppliers
4.2.1 Threat of Substitute
4.2.1 Threat of New Entrants
4.2.1 Competitive Rivalry
4.3. EXPERT OPINIONS
5. ANTIULCERANT DRUGS MARKET - KEY MARKET DYNAMICS
5.1. KEY MARKET DRIVERS
5.2. KEY MARKET RESTRAINTS
5.3. KEY MARKET OPPORTUNITIES
5.4. FUTURE TRENDS
5.5. IMPACT ANALYSIS OF DRIVERS AND RESTRAINTS
6. ANTIULCERANT DRUGS MARKET - GLOBAL MARKET ANALYSIS
6.1. ANTIULCERANT DRUGS - GLOBAL MARKET OVERVIEW
6.2. ANTIULCERANT DRUGS - GLOBAL MARKET AND FORECAST TO 2028
6.3. MARKET POSITIONING/MARKET SHARE
7. ANTIULCERANT DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - TYPE
7.1. OVERVIEW
7.2. TYPE MARKET FORECASTS AND ANALYSIS
7.3. PROTON PUMP INHIBITORS
7.3.1. Overview
7.3.2. Proton pump inhibitors Market Forecast and Analysis
7.4. H2 RECEPTOR ANTAGONISTS
7.4.1. Overview
7.4.2. H2 receptor antagonists Market Forecast and Analysis
7.5. ANTIBIOTICS
7.5.1. Overview
7.5.2. Antibiotics Market Forecast and Analysis
7.6. GASTRIC MUCOSAL PROTECTIVE DRUGS
7.6.1. Overview
7.6.2. Gastric mucosal protective drugs Market Forecast and Analysis
7.7. ANTACIDS
7.7.1. Overview
7.7.2. Antacids Market Forecast and Analysis
7.8. PROSTAGLANDIN AGONISTS
7.8.1. Overview
7.8.2. Prostaglandin agonists Market Forecast and Analysis
8. ANTIULCERANT DRUGS MARKET - REVENUE AND FORECASTS TO 2028 - DISEASE
8.1. OVERVIEW
8.2. DISEASE MARKET FORECASTS AND ANALYSIS
8.3. STOMACH ULCERS
8.3.1. Overview
8.3.2. Stomach Ulcers Market Forecast and Analysis
8.4. LEG ULCERS
8.4.1. Overview
8.4.2. Leg Ulcers Market Forecast and Analysis
8.5. PEPTIC ULCERS
8.5.1. Overview
8.5.2. Peptic Ulcers Market Forecast and Analysis
8.6. ESOPHAGEAL ULCER
8.6.1. Overview
8.6.2. Esophageal Ulcer Market Forecast and Analysis
8.7. BLEEDING ULCER
8.7.1. Overview
8.7.2. Bleeding Ulcer Market Forecast and Analysis
8.8. REFRACTORY ULCER
8.8.1. Overview
8.8.2. Refractory Ulcer Market Forecast and Analysis
8.9. STRESS ULCER
8.9.1. Overview
8.9.2. Stress Ulcer Market Forecast and Analysis
8.10. MOUTH ULCERS
8.10.1. Overview
8.10.2. Mouth Ulcers Market Forecast and Analysis
8.11. VENOUS STASIS ULCERS
8.11.1. Overview
8.11.2. Venous Stasis Ulcers Market Forecast and Analysis
8.12. NEUROPATHIC ULCERS
8.12.1. Overview
8.12.2. Neuropathic Ulcers Market Forecast and Analysis
8.13. ARTERIAL ULCERS
8.13.1. Overview
8.13.2. Arterial Ulcers Market Forecast and Analysis
8.14. PRESSURE ULCERS
8.14.1. Overview
8.14.2. Pressure Ulcers Market Forecast and Analysis
9. ANTIULCERANT DRUGS MARKET REVENUE AND FORECASTS TO 2028 - GEOGRAPHICAL ANALYSIS
9.1. NORTH AMERICA
9.1.1 North America Antiulcerant Drugs Market Overview
9.1.2 North America Antiulcerant Drugs Market Forecasts and Analysis
9.1.3 North America Antiulcerant Drugs Market Forecasts and Analysis - By Type
9.1.4 North America Antiulcerant Drugs Market Forecasts and Analysis - By Disease
9.1.5 North America Antiulcerant Drugs Market Forecasts and Analysis - By Countries
9.1.5.1 United States Antiulcerant Drugs Market
9.1.5.1.1 United States Antiulcerant Drugs Market by Type
9.1.5.1.2 United States Antiulcerant Drugs Market by Disease
9.1.5.2 Canada Antiulcerant Drugs Market
9.1.5.2.1 Canada Antiulcerant Drugs Market by Type
9.1.5.2.2 Canada Antiulcerant Drugs Market by Disease
9.1.5.3 Mexico Antiulcerant Drugs Market
9.1.5.3.1 Mexico Antiulcerant Drugs Market by Type
9.1.5.3.2 Mexico Antiulcerant Drugs Market by Disease
9.2. EUROPE
9.2.1 Europe Antiulcerant Drugs Market Overview
9.2.2 Europe Antiulcerant Drugs Market Forecasts and Analysis
9.2.3 Europe Antiulcerant Drugs Market Forecasts and Analysis - By Type
9.2.4 Europe Antiulcerant Drugs Market Forecasts and Analysis - By Disease
9.2.5 Europe Antiulcerant Drugs Market Forecasts and Analysis - By Countries
9.2.5.1 Germany Antiulcerant Drugs Market
9.2.5.1.1 Germany Antiulcerant Drugs Market by Type
9.2.5.1.2 Germany Antiulcerant Drugs Market by Disease
9.2.5.2 France Antiulcerant Drugs Market
9.2.5.2.1 France Antiulcerant Drugs Market by Type
9.2.5.2.2 France Antiulcerant Drugs Market by Disease
9.2.5.3 Italy Antiulcerant Drugs Market
9.2.5.3.1 Italy Antiulcerant Drugs Market by Type
9.2.5.3.2 Italy Antiulcerant Drugs Market by Disease
9.2.5.4 Spain Antiulcerant Drugs Market
9.2.5.4.1 Spain Antiulcerant Drugs Market by Type
9.2.5.4.2 Spain Antiulcerant Drugs Market by Disease
9.2.5.5 United Kingdom Antiulcerant Drugs Market
9.2.5.5.1 United Kingdom Antiulcerant Drugs Market by Type
9.2.5.5.2 United Kingdom Antiulcerant Drugs Market by Disease
9.2.5.6 Rest of Europe Antiulcerant Drugs Market
9.2.5.6.1 Rest of Europe Antiulcerant Drugs Market by Type
9.2.5.6.2 Rest of Europe Antiulcerant Drugs Market by Disease
9.3. ASIA-PACIFIC
9.3.1 Asia-Pacific Antiulcerant Drugs Market Overview
9.3.2 Asia-Pacific Antiulcerant Drugs Market Forecasts and Analysis
9.3.3 Asia-Pacific Antiulcerant Drugs Market Forecasts and Analysis - By Type
9.3.4 Asia-Pacific Antiulcerant Drugs Market Forecasts and Analysis - By Disease
9.3.5 Asia-Pacific Antiulcerant Drugs Market Forecasts and Analysis - By Countries
9.3.5.1 Australia Antiulcerant Drugs Market
9.3.5.1.1 Australia Antiulcerant Drugs Market by Type
9.3.5.1.2 Australia Antiulcerant Drugs Market by Disease
9.3.5.2 China Antiulcerant Drugs Market
9.3.5.2.1 China Antiulcerant Drugs Market by Type
9.3.5.2.2 China Antiulcerant Drugs Market by Disease
9.3.5.3 India Antiulcerant Drugs Market
9.3.5.3.1 India Antiulcerant Drugs Market by Type
9.3.5.3.2 India Antiulcerant Drugs Market by Disease
9.3.5.4 Japan Antiulcerant Drugs Market
9.3.5.4.1 Japan Antiulcerant Drugs Market by Type
9.3.5.4.2 Japan Antiulcerant Drugs Market by Disease
9.3.5.5 Rest of Asia-Pacific Antiulcerant Drugs Market
9.3.5.5.1 Rest of Asia-Pacific Antiulcerant Drugs Market by Type
9.3.5.5.2 Rest of Asia-Pacific Antiulcerant Drugs Market by Disease
9.4. MIDDLE EAST AND AFRICA
9.4.1 Middle East and Africa Antiulcerant Drugs Market Overview
9.4.2 Middle East and Africa Antiulcerant Drugs Market Forecasts and Analysis
9.4.3 Middle East and Africa Antiulcerant Drugs Market Forecasts and Analysis - By Type
9.4.4 Middle East and Africa Antiulcerant Drugs Market Forecasts and Analysis - By Disease
9.4.5 Middle East and Africa Antiulcerant Drugs Market Forecasts and Analysis - By Countries
9.4.5.1 South Africa Antiulcerant Drugs Market
9.4.5.1.1 South Africa Antiulcerant Drugs Market by Type
9.4.5.1.2 South Africa Antiulcerant Drugs Market by Disease
9.4.5.2 U.A.E Antiulcerant Drugs Market
9.4.5.2.1 U.A.E Antiulcerant Drugs Market by Type
9.4.5.2.2 U.A.E Antiulcerant Drugs Market by Disease
9.4.5.3 Rest of Middle East and Africa Antiulcerant Drugs Market
9.4.5.3.1 Rest of Middle East and Africa Antiulcerant Drugs Market by Type
9.4.5.3.2 Rest of Middle East and Africa Antiulcerant Drugs Market by Disease
9.5. SOUTH AND CENTRAL AMERICA
9.5.1 South and Central America Antiulcerant Drugs Market Overview
9.5.2 South and Central America Antiulcerant Drugs Market Forecasts and Analysis
9.5.3 South and Central America Antiulcerant Drugs Market Forecasts and Analysis - By Type
9.5.4 South and Central America Antiulcerant Drugs Market Forecasts and Analysis - By Disease
9.5.5 South and Central America Antiulcerant Drugs Market Forecasts and Analysis - By Countries
9.5.5.1 Brazil Antiulcerant Drugs Market
9.5.5.1.1 Brazil Antiulcerant Drugs Market by Type
9.5.5.1.2 Brazil Antiulcerant Drugs Market by Disease
9.5.5.2 Argentina Antiulcerant Drugs Market
9.5.5.2.1 Argentina Antiulcerant Drugs Market by Type
9.5.5.2.2 Argentina Antiulcerant Drugs Market by Disease
9.5.5.3 Rest of South and Central America Antiulcerant Drugs Market
9.5.5.3.1 Rest of South and Central America Antiulcerant Drugs Market by Type
9.5.5.3.2 Rest of South and Central America Antiulcerant Drugs Market by Disease
10. INDUSTRY LANDSCAPE
10.1. MERGERS AND ACQUISITIONS
10.2. AGREEMENTS, COLLABORATIONS AND JOIN VENTURES
10.3. NEW PRODUCT LAUNCHES
10.4. EXPANSIONS AND OTHER STRATEGIC DEVELOPMENTS
11. ANTIULCERANT DRUGS MARKET, KEY COMPANY PROFILES
11.1. DR. REDDY'S LABORATORIES, LTD
11.1.1. Key Facts
11.1.2. Business Description
11.1.3. Products and Services
11.1.4. Financial Overview
11.1.5. SWOT Analysis
11.1.6. Key Developments
11.2. CIPLA
11.2.1. Key Facts
11.2.2. Business Description
11.2.3. Products and Services
11.2.4. Financial Overview
11.2.5. SWOT Analysis
11.2.6. Key Developments
11.3. GLENMARK
11.3.1. Key Facts
11.3.2. Business Description
11.3.3. Products and Services
11.3.4. Financial Overview
11.3.5. SWOT Analysis
11.3.6. Key Developments
11.4. ARISTO PHARMA
11.4.1. Key Facts
11.4.2. Business Description
11.4.3. Products and Services
11.4.4. Financial Overview
11.4.5. SWOT Analysis
11.4.6. Key Developments
11.5. TAKEDA PHARMACEUTICAL COMPANY LIMITED
11.5.1. Key Facts
11.5.2. Business Description
11.5.3. Products and Services
11.5.4. Financial Overview
11.5.5. SWOT Analysis
11.5.6. Key Developments
11.6. SALIX PHARMACEUTICALS
11.6.1. Key Facts
11.6.2. Business Description
11.6.3. Products and Services
11.6.4. Financial Overview
11.6.5. SWOT Analysis
11.6.6. Key Developments
11.7. ZYDUS CADILA
11.7.1. Key Facts
11.7.2. Business Description
11.7.3. Products and Services
11.7.4. Financial Overview
11.7.5. SWOT Analysis
11.7.6. Key Developments
11.8. PFIZER, INC
11.8.1. Key Facts
11.8.2. Business Description
11.8.3. Products and Services
11.8.4. Financial Overview
11.8.5. SWOT Analysis
11.8.6. Key Developments
11.9. FOURRTS
11.9.1. Key Facts
11.9.2. Business Description
11.9.3. Products and Services
11.9.4. Financial Overview
11.9.5. SWOT Analysis
11.9.6. Key Developments
11.10. HIMALAYA WELLNESS COMPANY
11.10.1. Key Facts
11.10.2. Business Description
11.10.3. Products and Services
11.10.4. Financial Overview
11.10.5. SWOT Analysis
11.10.6. Key Developments
12. APPENDIX
12.1. ABOUT THE INSIGHT PARTNERS
12.2. GLOSSARY OF TERMS
"
- Dr. Reddy's Laboratories, Ltd
- Cipla
- Glenmark
- Aristo Pharma
- Takeda Pharmaceutical Company Limited
- Salix Pharmaceuticals
- Zydus Cadila
- Pfizer, Inc
- Fourrts
- Himalaya Wellness Company
- Embiotic Laboratories.
- Glaxosmithkline, Plc
- Aurobindo Pharma
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.